Janux Therapeutics Ownership

JANX Stock  USD 26.38  0.30  1.15%   
The majority of Janux Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Janux Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Janux Therapeutics. Please pay attention to any change in the institutional holdings of Janux Therapeutics as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as Janux Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Janux Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Janux Stock Ownership Analysis

About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.54. Some equities with similar Price to Book (P/B) outperform the market in the long run. Janux Therapeutics recorded a loss per share of 1.36. The entity had not issued any dividends in recent years. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. Janux Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To learn more about Janux Therapeutics call David Campbell at 858 751 4493 or check out https://www.januxrx.com.

Janux Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Janux Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Janux Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Janux Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Kung Winston over a month ago
Acquisition by Kung Winston of 3750 shares of Janux Therapeutics subject to Rule 16b-3
 
Janeen Doyle over a month ago
Acquisition by Janeen Doyle of 44000 shares of Janux Therapeutics subject to Rule 16b-3
 
Meyer Andrew Hollman over two months ago
Disposition of 400 shares by Meyer Andrew Hollman of Janux Therapeutics at 32.6034 subject to Rule 16b-3
 
Meyer Andrew Hollman over three months ago
Disposition of 3334 shares by Meyer Andrew Hollman of Janux Therapeutics at 30.0 subject to Rule 16b-3
 
Meyer Andrew Hollman over three months ago
Acquisition by Meyer Andrew Hollman of 3334 shares of Janux Therapeutics at 4.21 subject to Rule 16b-3
 
Diraimondo Thomas over three months ago
Acquisition by Diraimondo Thomas of 84000 shares of Janux Therapeutics at 53.24 subject to Rule 16b-3
 
Ra Capital Management, L.p. over three months ago
Acquisition by Ra Capital Management, L.p. of 110206 shares of Janux Therapeutics at 31.02 subject to Rule 16b-3
 
Avalon Ventures Xi, L.p. over three months ago
Acquisition by Avalon Ventures Xi, L.p. of 2070 shares of Janux Therapeutics at 13.22 subject to Rule 16b-3
 
Zachariah Mciver over three months ago
Insider Trading
 
Avalon Ventures Xi, L.p. over three months ago
Disposition of 40803 shares by Avalon Ventures Xi, L.p. of Janux Therapeutics at 47.77 subject to Rule 16b-3
 
Meyer Andrew Hollman over three months ago
Disposition of 100 shares by Meyer Andrew Hollman of Janux Therapeutics at 43.6 subject to Rule 16b-3
 
Meyer Andrew Hollman over six months ago
Disposition of 5768 shares by Meyer Andrew Hollman of Janux Therapeutics at 54.5111 subject to Rule 16b-3

Janux Therapeutics Outstanding Bonds

Janux Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Janux Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Janux bonds can be classified according to their maturity, which is the date when Janux Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.